COMP <GO>
ADPT vs UNH // 10Y YIELD & FRED MACRO BETA
Adaptive Biotechnologies Corporation (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ADPT 3
— UNH 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ADPT
LAST: $26.64 (-5.43%) • MKT CAP: $4.50B
macro-sensitivity
1.01
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
macro-sensitivity
0.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 88.57% | -14.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | 11.47% | -23.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | 6.48% | -7.57 | UNH | /fcf-yield <GO> |
| Operating Margin | -20.60% | 4.82% | -25.42 | UNH | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 3.14% | -24.64 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 6.46% | +48.34 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 3.12 | +3.20 | ADPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.3 | 56.0 | -4.80 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.01 | 0.33 | +0.68 | ADPT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | 17.1x | +8.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.50B | $364.66B | -$360.16B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | UNH REV | ADPT GROSS % | UNH GROSS % | ADPT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $447.57B | 74.2% | 88.7% | -$48.9M | $16.07B |
| FY 2024 | $179.0M | $400.28B | 59.7% | 88.3% | -$98.9M | $20.70B |
| FY 2023 | $170.3M | $371.62B | 44.0% | 89.6% | -$164.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
UNH // BETA 0.33